Form 4 Filing for Artiva Biotherapeutics, Inc.

This filing details transactions made by RA Capital Management, L.P. and its associated funds regarding common stock of Artiva Biotherapeutics, Inc. (ARTV). On June 25, 2026, 31,000 shares were acquired at a weighted average price of $8.88, bringing the total holdings to 16,794,043 shares. On June 26, 2026, an additional 1,876 shares were acquired at a weighted average price of $8.98, increasing the total holdings to 16,795,919 shares. The filing also notes that Laura Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors. RA Capital Management, L.P. acts as the investment manager for several funds, including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., and RA Capital Nexus Fund III, L.P. Peter Kolchinsky and Rajeev Shah are identified as managing members of the general partner of the Adviser.